Rutgers University–Camden Explores HIV Treatment Uptake for Long-Acting Injections
Long-acting HIV injections offer an alternative to daily medication, yet overall HIV treatment uptake remains limited. Research led by Rutgers Health highlights this gap between patient interest and actual use. Understanding the barriers that prevent wider adoption can help clinicians and public health professionals improve care for people living with HIV.
Examining Preferences and Real-World Use
A recent survey of 801 people living with HIV in Boston, Chapel Hill, and San Diego found that 68% would prefer a long-acting antiretroviral shot every two months instead of a daily pill. Despite this interest, only a small fraction of patients receive these injections. The disparity suggests that logistical, clinical, and personal factors influence whether patients transition from preference to actual use.
Long-acting long-acting injections were approved by the Food and Drug Administration in 2021 for monthly dosing and in 2022 for every-two-month dosing. These regimens combine two drugs administered in a medical office. For some patients, injections reduce the need to remember daily doses, lower the risk of missed doses, and minimize concerns about pill bottles revealing an HIV diagnosis at home.
Factors That Influence Interest in Injectable Therapy
Researchers identified several factors associated with a stronger preference for injectable options. Patients who felt overwhelmed by daily pills were more likely to favor injections. This perception of high pill burden often reflects broader challenges in maintaining a daily medication routine.
Conversely, older participants were less inclined to choose injections, often because they were already managing multiple daily medications. Fear of needles and long travel times to clinics also reduced interest in injectable therapy. These practical considerations shape how patients evaluate the benefits and drawbacks of different treatment options.
Privacy concerns emerged as an important theme. Some patients prefer not to keep pills at home to avoid unintentional disclosure of their HIV status. This desire for confidentiality can make long-acting injections appealing, particularly for individuals who share living spaces or worry about stigma.
Clinical Considerations and Provider Perspectives
Clinical factors also affect treatment decisions. Patients with detectable viral loads were more likely to express interest in monthly injections. However, providers may hesitate to offer injectable therapy to these patients, as consistent clinic attendance is required for dosing. This tension highlights the need for clear communication about adherence and appointment reliability.
Racial differences were also observed in the study. Black participants were nearly twice as likely as white participants to prefer long-acting therapy. These differences may reflect varied experiences with stigma, privacy, and trust in medical settings. Addressing these disparities is essential for equitable HIV treatment uptake.
Supporting Informed Decisions in Clinical Settings
Based on these findings, researchers have developed a tool to help caregivers guide patients through treatment choices. This resource explains how daily pills and long-acting injections work while outlining the advantages and limitations of each approach. Early testing of the tool suggests that structured conversations can clarify patient priorities and reduce uncertainty about switching therapies.
Clinics that routinely ask patients about their lifestyle and preferences may be better positioned to align treatment plans with individual needs. As newer long-acting options enter development, including twice-yearly shots, these conversations will become increasingly important. Patients benefit when providers present options clearly rather than assuming that one approach fits all.
Advancing Access Through Education and Outreach
Expanding the use of injectable HIV therapy requires attention to systemic barriers. Transportation, scheduling flexibility, and clinic policies all influence whether patients can realistically attend regular injection appointments. Simplifying these logistics can help more people transition from interest to actual use.
Educational initiatives that address needle anxiety and misinformation about injectable therapy may also increase comfort with these options. When patients understand what to expect during and after injections, they are more likely to consider them as viable alternatives to daily pills.
Efforts to improve HIV treatment uptake must also consider the role of trust in patient-provider relationships. Patients who feel heard and respected are more likely to engage in discussions about treatment changes. This trust is especially important when weighing the pros and cons of long-term therapy adjustments.
Looking Ahead in HIV Care
As treatment options evolve, maintaining a focus on practical, patient-centered care remains critical. Research institutions such as Rutgers University–Camden contribute to this work by studying how preferences translate into real-world decisions. These insights help shape clinical tools and outreach strategies that support informed choices.
Patients considering a switch to injectable therapy can benefit from discussing their concerns with a knowledgeable provider. Exploring whether an every-two-month regimen fits into daily life is a practical first step. For those interested in learning more about available options, resources are available to support this process.
Explore available programs and resources to understand how different treatment approaches can align with individual health goals and lifestyles.
Sustained progress in HIV care depends on addressing both medical and social factors that influence treatment decisions. By reducing barriers and expanding access to information, clinicians and public health professionals can help more patients benefit from long-acting therapy when it meets their needs.
Learn more about HIV treatment options and how evolving therapies may fit into comprehensive care plans.
Ongoing research and clinical innovation will continue to shape the future of HIV treatment. Patients who stay informed and engaged with their care teams are better positioned to make choices that support long-term health and well-being.
Discover if injectable HIV therapy aligns with your health priorities and daily routine by reviewing current options with a qualified provider.
